Thermo Fisher Scientific has announced a strategic partnership with SHL Medical to integrate autoinjector assembly at its sterile fill-finish site in Ridgefield.
At the same time, the brand also revealed it would expand sterile fill-finish and autoinjector final assembly capacity at its Ridgefield, NJ site, to meet increased demand for patient-centric, self-administered injectable therapies, which continues to grow across multiple therapeutic areas.
It says that these investments will help establish a fully integrated US-based offering spanning sterile manufacturing, device assembly and commercial packaging for drug-device combination products.
Thermo Fisher's collaboration with SHL Medical will also enable integration of SHL Medical's Molly autoinjector platform with Thermo Fisher's sterile manufacturing network, creating a seamless, end-to-end solution from drug product to finished device.
Thermo Fisher acquired the Ridgefield facility from Sanofi in September 2025 as part of its strategy to expand its US manufacturing presence.
The site is being developed into a leading North American hub for integrated sterile fill-finish processes, autoinjector final assembly and packaging. This development aims to increase domestic capacity and better support customer supply chains.
"The collaboration with SHL Medical, a global leader in autoinjectors and our expansion in Ridgefield are important steps in helping our customers meet growing demand," said Michelle Logan, Vice President, Drug Product – Steriles, North America, Thermo Fisher.
By fully integrating fill-finish with device assembly, we can simplify supply chains, accelerate timelines and ultimately support our customers in delivering critical therapies to patients more efficiently.
According to Thermo Fisher's statement, under the new agreement, the pair will provide integrated support for SHL Medical's Molly autoinjector platform at the Ridgefield site, including final device assembly, packaging and distribution.
The collaboration is designed to simplify development and manufacturing for pharmaceutical and biotechnology customers, supporting a streamlined path from drug product manufacturing through commercialisation.
"This collaboration with Thermo Fisher represents a significant milestone for SHL Medical and for the customers we jointly serve," said Markus Puusepp, Chief Growth Officer, SHL Medical.
By combining SHL Medical's proven Molly autoinjector platform and global device expertise with Thermo Fisher's leading sterile fill-finish and commercial manufacturing capabilities, we are creating a powerful, integrated solution.
"This installation in Ridgefield underscores our shared commitment to supporting the growing demand for high-quality, patient-centric combination products and accelerating time to market for innovative therapies worldwide."
The addition of autoinjector capabilities in Ridgefield complements Thermo Fisher's global network, including sites in Allentown, Pa., Horsham, UK and planned capacity in Greenville, N.C., creating a scalable platform across development and commercial stages.